{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T14:36:26Z","timestamp":1787841386663,"version":"build-2784847793"},"reference-count":20,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,5]]},"abstract":"Abstract<\/jats:title>\n \n Background:<\/jats:title>\n Rosacea is a chronic inflammatory skin disease. Previous studies have determined that IL-36, IL-37, and IL-38 may play a role in the pathogenesis of various inflammatory diseases.<\/jats:p>\n <\/jats:sec>\n \n Aims and Objectives:<\/jats:title>\n The present study aims to evaluate the relationship of these cytokines with rosacea.<\/jats:p>\n <\/jats:sec>\n \n Materials and Methods:<\/jats:title>\n A total of 100 individuals, including 50 patients with rosacea and 50 healthy controls, were included in the study. IL-36, IL-37, and IL-38 levels were measured using the ELISA method by taking serum samples from all participants.<\/jats:p>\n <\/jats:sec>\n \n Results:<\/jats:title>\n \n The mean serum levels of IL-36, IL-37, and IL-38 in the patient group were 52.17 \u00b1 24.07 pg\/ml, 18.46 \u00b1 8.18 pg\/ml, and 25.74 \u00b1 8.36 ng\/l, respectively. The mean serum levels of IL-36, IL-37, and IL-38 in the control group were 32.99 \u00b1 19.90 pg\/ml, 44.61 \u00b1 22.27 pg\/ml, and 45.61 \u00b1 17.32 ng\/l, respectively. The difference between the serum levels of IL-36, IL-37, and IL-38 in the patient and control groups was statistically significant (\n P<\/jats:italic>\n < 0.001).\n <\/jats:p>\n <\/jats:sec>\n \n Conclusion:<\/jats:title>\n Based on these findings, an increase in IL-36 and a decrease in IL-37 and IL-38 may contribute to the pathogenesis of rosacea. Future rosacea treatments could target and\/or interact with these possible steps in the pathogenesis of rosacea.<\/jats:p>\n <\/jats:sec>","DOI":"10.4103\/ijd.ijd_470_23","type":"journal-article","created":{"date-parts":[[2024,7,2]],"date-time":"2024-07-02T13:06:32Z","timestamp":1719925592000},"page":"232-237","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["Important Roles of Interleukin-36, Interleukin-37, and Interleukin-38 Cytokines in the Pathogenesis of Rosacea"],"prefix":"10.4103","volume":"69","author":[{"given":"Alper","family":"Ekinci","sequence":"first","affiliation":[{"name":"From the Department of Dermatology, Kahramanmaras Necip Fazil City Hospital, Kahramanmaras, Turkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sevilay O.","family":"Kilic","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Istanbul Medipol University, Faculty of Medicine, Istanbul, Turkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nesrin","family":"Demir","sequence":"additional","affiliation":[{"name":"Department of Immunology, Antalya Bilim University, Faculty of Dentistry, Antalya, Turkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Duygu","family":"Siddikoglu","sequence":"additional","affiliation":[{"name":"Department of Biostatistics, Canakkale Onsekiz Mart University, Faculty of Medicine, Canakkale, Turkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2024,6,26]]},"reference":[{"key":"R1-20240829","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1067\/mjd.2002.120625","article-title":"Standard classification of rosacea:Report of the national rosacea society expert committee on the classification and staging of rosacea","volume":"46","author":"Wilkin","year":"2002","journal-title":"J Am Acad Dermatol"},{"issue":"6 Suppl 1","key":"R2-20240829","doi-asserted-by":"crossref","first-page":"S27","DOI":"10.1016\/j.jaad.2013.04.043","article-title":"Rosacea:Current state of epidemiology","volume":"69","author":"Tan","year":"2013","journal-title":"J Am Acad Dermatol"},{"key":"R3-20240829","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.det.2017.11.001","article-title":"Rosacea pathogenesis","volume":"36","author":"Ahn","year":"2018","journal-title":"Dermatol Clin"},{"key":"R4-20240829","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.3390\/ijms20061257","article-title":"IL-36, IL-37, and IL-38 cytokines in skin and joint inflammation:A comprehensive review of their therapeutic potential","volume":"20","author":"Boutet","year":"2019","journal-title":"Int J Mol Sci"},{"key":"R5-20240829","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1001\/jama.2013.281053","article-title":"World Medical Association Declaration of Helsinki:Ethical principles for medical research involving human subjects","volume":"310","year":"2013","journal-title":"JAMA"},{"key":"R6-20240829","article-title":"Biomarkers in rosacea:A systematic review","author":"Geng","year":"2023","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"R7-20240829","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1111\/exd.13702","article-title":"Increased expression of IL-33 in rosacea skin and UVB-irradiated and LL-37-treated HaCaT cells","volume":"27","author":"Suhng","year":"2018","journal-title":"Exp Dermatol"},{"key":"R8-20240829","doi-asserted-by":"crossref","first-page":"2532","DOI":"10.3389\/fimmu.2019.02532","article-title":"Biology of IL-36 signaling and its role in systemic inflammatory diseases","volume":"10","author":"Yuan","year":"2019","journal-title":"Front Immunol"},{"key":"R9-20240829","doi-asserted-by":"crossref","first-page":"3058640","DOI":"10.1155\/2018\/3058640","article-title":"Reviews of interleukin-37:Functions, receptors, and roles in diseases","volume":"2018","author":"Jia","year":"2018","journal-title":"BioMed Res Int"},{"key":"R10-20240829","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.3389\/fimmu.2018.01462","article-title":"Role of interleukin-38 in chronic inflammatory diseases:A comprehensive review","volume":"9","author":"Xu","year":"2018","journal-title":"Front Immunol"},{"key":"R11-20240829","doi-asserted-by":"crossref","first-page":"345","DOI":"10.3390\/biom9080345","article-title":"IL-38:A new player in inflammatory autoimmune disorders","volume":"9","author":"Xie","year":"2019","journal-title":"Biomolecules"},{"key":"R12-20240829","doi-asserted-by":"crossref","first-page":"109705","DOI":"10.1016\/j.biopha.2019.109705","article-title":"The role of IL-37 in skin and connective tissue diseases","volume":"122","author":"Pan","year":"2020","journal-title":"Biomed Pharmacother"},{"key":"R13-20240829","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1684\/ecn.2019.0430","article-title":"IL-38 serum levels in patients with Behcet's disease and the relationship with clinical features","volume":"30","author":"Zarrabi","year":"2019","journal-title":"Eur Cytokine Netw"},{"key":"R14-20240829","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1111\/imr.12605","article-title":"Suppression of inflammation and acquired immunity by IL-37","volume":"281","author":"Cavalli","year":"2018","journal-title":"Immunol Rev"},{"key":"R15-20240829","doi-asserted-by":"crossref","first-page":"2153","DOI":"10.3390\/biomedicines11082153","article-title":"Exploring the pathogenesis and mechanism-targeted treatments of rosacea:Previous understanding and updates","volume":"11","author":"Chen","year":"2023","journal-title":"Biomedicines"},{"key":"R16-20240829","doi-asserted-by":"crossref","first-page":"2933","DOI":"10.1007\/s13555-023-01048-1","article-title":"Emerging medical therapies in rosacea:A narrative review","volume":"13","author":"Choe","year":"2023","journal-title":"Dermatol Ther"},{"key":"R17-20240829","doi-asserted-by":"crossref","first-page":"1239869","DOI":"10.3389\/fmed.2023.1239869","article-title":"JAK1 inhibitor abrocitinib for the treatment of steroid-induced rosacea:Case series","volume":"10","author":"Xu","year":"2023","journal-title":"Front Med"},{"key":"R18-20240829","doi-asserted-by":"crossref","first-page":"2519","DOI":"10.2147\/CCID.S392280","article-title":"Tofacitinib for the treatment of steroid-induced rosacea","volume":"15","author":"Li","year":"2022","journal-title":"Clin Cosmet Investig Dermatol"},{"key":"R22-20240829","first-page":"660","article-title":"Evaluation of a first-in-class proteasome inhibitor in patients with moderate to severe rosacea","volume":"20","author":"Jackson","year":"2021","journal-title":"J Drugs Dermatol JDD"},{"key":"R23-20240829","first-page":"279","article-title":"Targeting IL-36 in inflammatory skin diseases","volume":"37","author":"Fukaura","year":"2023","journal-title":"BioDrugs Clin Immunother Biopharm Gene Ther"}],"container-title":["Indian Journal of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/ijd.ijd_470_23","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T13:52:31Z","timestamp":1787838751000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/ijd.ijd_470_23"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5]]},"references-count":20,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.4103\/ijd.ijd_470_23","relation":{},"ISSN":["0019-5154","1998-3611"],"issn-type":[{"value":"0019-5154","type":"print"},{"value":"1998-3611","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5]]},"assertion":[{"value":"2023-05-01","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-02-01","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}